For the quarter ending 2025-09-30, DAWN has $513,780K in assets. $62,912K in debts. $43,277K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 43,277 | 35,622 | ||
| Short-term investments | 408,303 | 417,481 | ||
| Accounts receivable, net | 16,697 | 19,669 | ||
| Inventory | 7,061 | 6,543 | ||
| Prepaid expenses and other current assets | 14,633 | 15,113 | ||
| Total current assets | 489,971 | 494,428 | ||
| Property and equipment, net | 2,227 | 2,317 | ||
| Operating leaseright-of-useasset | 2,450 | 2,499 | ||
| 2025 (remaining) | 795 | - | ||
| 2026 | 3,180 | - | ||
| 2027 | 3,180 | - | ||
| 2028 | 3,180 | - | ||
| 2029 | 3,180 | - | ||
| Thereafter | 5,300 | - | ||
| Intangible assets, net | 18,815 | 19,610 | ||
| Deposits and other long-term assets | 317 | 183 | ||
| Total assets | 513,780 | 519,037 | ||
| Accounts payable | 5,778 | 5,090 | ||
| Accrued expenses and other current liabilities | 48,210 | 44,131 | ||
| Current portion of deferred revenue | 2,317 | 1,847 | ||
| Current portion of operating lease liabilities | 161 | 153 | ||
| Total current liabilities | 56,466 | 51,221 | ||
| Long-term portion of deferred revenue | 2,953 | 3,371 | ||
| Long-term portion of operating lease liabilities | 2,732 | 2,850 | ||
| Other long-term liability | 761 | 761 | ||
| Total liabilities | 62,912 | 58,203 | ||
| Common stock, 0.0001 par value 500,000,000 shares authorized as of september 30, 2025 and december 31, 2024 102,675,502 and 101,116,162 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 10 | 10 | ||
| Additionalpaid-in-capital | 1,090,914 | 1,081,315 | ||
| Accumulated other comprehensive income | 69 | -92 | ||
| Accumulated deficit | -640,125 | -620,399 | ||
| Total stockholders' equity | 450,868 | 460,834 | ||
| Total liabilities and stockholders' equity | 513,780 | 519,037 | ||
Day One Biopharmaceuticals, Inc. (DAWN)
Day One Biopharmaceuticals, Inc. (DAWN)